Literature DB >> 8596867

Cirrhosis of the liver: MR imaging with mangafodipir trisodium (Mn-DPDP).

T Murakami1, R L Baron, M P Federle, M S Peterson, J H Oliver, P L Davis, S R Confer.   

Abstract

PURPOSE: To evaluate the usefulness of manganese (II) N,N'-dipyridoxylethylenediamine-N,N'-diacetate 5,5'-bis(phosphate) (Mn-DPDP) in magnetic resonance (MR) imaging of cirrhotic livers.
MATERIALS AND METHODS: Fifty-eight patients (mean age, 58.8 years), 29 with and 29 without cirrhosis, underwent MR imaging before and after intravenous administration of 5 mumol/kg Mn-DPDP. Enhancement effects were assessed quantitatively and qualitatively. Histologic confirmation was obtained in 51 patients.
RESULTS: Liver parenchyma in both patient groups enhanced significantly on T1-weighted spin-echo and gradient-recalled-echo (GRE) images (P < .01). However, cirrhotic livers enhanced significantly less than noncirrhotic livers on T1-weighted GRE images (P < .05). Fourteen cirrhotic livers had heterogeneous enhancement of parenchyma; enhancement was more prominent on GRE images. Decreased enhancement was seen in patients with confluent fibrosis (n = 5), diffuse fibrosis (n = 6), and siderotic regenerating nodules (n = 4). Increased enhancement was seen in patients with benign regenerating nodules (n = 4).
CONCLUSION: Mn-DPDP is useful in patients with cirrhosis.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8596867     DOI: 10.1148/radiology.198.2.8596867

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  4 in total

1.  Mn-DPDP-enhanced 24-h delayed-scan MRI of hepatocellular carcinoma is correlated with histology.

Authors:  Deng-Bin Wang; Kang-Rong Zhou; Meng-Su Zeng; Ke-Min Chen; Yi-Xiang J Wang
Journal:  Eur Radiol       Date:  2003-06-12       Impact factor: 5.315

2.  Safety and efficacy of Mangafodipir trisodium in patients with liver lesions and cirrhosis.

Authors:  Luis Martí-Bonmatí; Amura F Fog; Bart Op de Beeck; Pauline Kane; Hans Fagertun
Journal:  Eur Radiol       Date:  2002-12-19       Impact factor: 5.315

3.  Diagnosis and measurement of liver fibrosis by MRI in bile duct ligated rats.

Authors:  Christophe Aubé; Frédéric Moal; Frédéric Oberti; Jérôme Roux; Vincent Croquet; Yves Gallois; Christophe Argaud; Christine Caron; Paul Calès
Journal:  Dig Dis Sci       Date:  2007-04-11       Impact factor: 3.199

Review 4.  Hepatobiliary contrast agents for contrast-enhanced MRI of the liver: properties, clinical development and applications.

Authors:  Peter Reimer; Günter Schneider; Wolfgang Schima
Journal:  Eur Radiol       Date:  2004-02-25       Impact factor: 5.315

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.